EP3302485

CERDULATINIB FOR THE TREATMENT OF B-CELL MALIGNANCIES

  • Status:
    EP einkaleyfi: Þýðing ekki lögð inn
  • EP appl. date:
    27.5.2016
  • EP published:
    12.7.2023
  • EP application number:
    16804177.0
  • Max expiry date:
    26.5.2036
  • Title in English:
    CERDULATINIB FOR THE TREATMENT OF B-CELL MALIGNANCIES
  • Language of the patent:
    English

Timeline

Today
27.5.2016EP application
12.7.2023EP Publication

Owner

  • Name:
    Alexion Pharmaceuticals, Inc.
  • Address:
    121 Seaport Boulevard, Boston, MA 02210, US

Inventor

  • Name:
    PANDEY, Anjali
  • Address:
    South San Francisco, California 94080, US
  • Name:
    COFFEY, Gregory
  • Address:
    South San Francisco, California 94080, US
  • Name:
    LEEDS, Janet
  • Address:
    South San Francisco, California 94080, US

Priority

  • Number:
    201562168530 P
  • Date:
    29.5.2015
  • Country:
    US
  • Number:
    201562263582 P
  • Date:
    4.12.2015
  • Country:
    US

Classification

  • Categories:
    A61K 31/506, A61P 35/02

Upload documents